Babu Rao Vundinti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Babu Rao Vundinti has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
Somprakash Dhangar
Department of Cytogenetics, ICMR-National Institute of Immunoheamatology, Mumbai, India
21 shared publicationsKanjaksha Ghosh
National Institute of Immunohematology, Parel, Mumbai, India
16 shared publicationsSeema Korgaonkar
Department of Cytogenetics, National Institute of Immunohematology (ICMR), K.E.M Hospital Campus, Parel, Mumbai, Maharashtra, India
16 shared publicationsChandrakala Shanmukhaiah
Department of Hematology, 10th Floor, New Multistoried Building, KEM Hospital, Parel, Mumbai, India
15 shared publicationsAvani Solanki
Department of Cytogenetics, ICMR—National Institute of Immunohematology K.E.M. Hospital Campus Mumbai Maharashtra India
9 shared publicationsAruna Rajendran
Department of Pediatric Hematology, Institute of Child Health and Hospital for Children, Chennai, India
8 shared publications
Latest Publications
- 14 September 2026
- Published by Springer Nature in European Journal of Human Genetics
- p. 1-10
Genomic and computational analysis of variants in telomere regulatory genes in subjects with bone marrow failure
- 14 September 2026
- Published by Springer Nature in European Journal of Human Genetics
- p. 1-10
Genomic and computational analysis of variants in telomere regulatory genes in subjects with bone marrow failure
- 27 March 2026
- Published by Springer Nature in Human Genetics
- Vol. 145 (1) , 35
DNA methylation signatures from peripheral blood revealed epigenetic alterations in Fanconi anemia
- 27 March 2026
- Published by Springer Nature in Human Genetics
- Vol. 145 (1) , 35
DNA methylation signatures from peripheral blood revealed epigenetic alterations in Fanconi anemia
- 29 December 2025
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 93 (2) , 208-209
A Rare Variant in RPS26 Gene Causing Variable Phenotype of Diamond-Blackfan Anemia Type 10 (DBA10) in an Indian Family
- 29 December 2025
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 93 (2) , 208-209
A Rare Variant in RPS26 Gene Causing Variable Phenotype of Diamond-Blackfan Anemia Type 10 (DBA10) in an Indian Family
- 28 June 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-9
Association of TGF-β1 -509 C > T (rs1800469) polymorphism with bone marrow failure severity in Fanconi anemia subjects
- 28 June 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-9
Association of TGF-β1 -509 C > T (rs1800469) polymorphism with bone marrow failure severity in Fanconi anemia subjects
- 17 March 2025
- Published by Elsevier in Leukemia Research
- Vol. 152, 107679
Comprehensive analysis of tyrosine kinase domain mutations and imatinib resistance in chronic myeloid leukemia patients
- 17 March 2025
- Published by Elsevier in Leukemia Research
- Vol. 152, 107679
Comprehensive analysis of tyrosine kinase domain mutations and imatinib resistance in chronic myeloid leukemia patients
- 13 February 2025
- Published by Springer Nature in Journal of Human Genetics
- Vol. 70 (4) , 207-213
Phenotype puzzle: the role of novel LMBRD1 gene variant in Cbl deficiency causing Dyskeratosis Congenita-like clinical manifestations
Cobalamin (Cbl) metabolism deficiencies are a heterogeneous group (CblA, CblB, CblC, CblD, CblE, CblF, CblG) of autosomal recessive disorders. CblF deficiency occurs due to mutations in LMBRD1 gene, causing variable phenotype, including neurological, haematological, developmental and dermatological defects. Here, we describe a 15-year-old male, presented with clinical features of Dyskeratosis Congenita (DC) such as dystrophic nails, skin discoloration with additional clinical features of uniform reticulate-brown hued hyperpigmentation, developmental delay, mild intellectual disability, mucositis and anemia. Genomic analysis using high throughput next generation sequencing (NGS) identified a novel splice site deletion (c.562+4_562+7del) in the LMBRD1 gene resulting in Cbl deficiency. cDNA sequencing elucidated exon 6 skipping as a consequence of a novel deletion, resulting in significant structural alterations of LMBD1 protein, which was further validated by in-silico computational analysis. Computational modeling and docking studies revealed a reduced interaction affinity between the LMBD1 protein and its partner protein ABCD4. These alterations contribute to a disrupted cascade mechanism in cobalamin (Cbl) metabolism resulting in development of variable clinical phenotypes. In our case, the proband was treated with intravenous hydroxocobalamin therapy and follow up showed a significant improvement in clinical symptoms of skin hyperpigmentation, angular cheilitis and aphthous ulcers. Hence the genomic analysis is essentially important for the appropriate genetic counseling and management of the disease.
- 13 February 2025
- Published by Springer Nature in Journal of Human Genetics
- Vol. 70 (4) , 207-213
Phenotype puzzle: the role of novel LMBRD1 gene variant in Cbl deficiency causing Dyskeratosis Congenita-like clinical manifestations
Cobalamin (Cbl) metabolism deficiencies are a heterogeneous group (CblA, CblB, CblC, CblD, CblE, CblF, CblG) of autosomal recessive disorders. CblF deficiency occurs due to mutations in LMBRD1 gene, causing variable phenotype, including neurological, haematological, developmental and dermatological defects. Here, we describe a 15-year-old male, presented with clinical features of Dyskeratosis Congenita (DC) such as dystrophic nails, skin discoloration with additional clinical features of uniform reticulate-brown hued hyperpigmentation, developmental delay, mild intellectual disability, mucositis and anemia. Genomic analysis using high throughput next generation sequencing (NGS) identified a novel splice site deletion (c.562+4_562+7del) in the LMBRD1 gene resulting in Cbl deficiency. cDNA sequencing elucidated exon 6 skipping as a consequence of a novel deletion, resulting in significant structural alterations of LMBD1 protein, which was further validated by in-silico computational analysis. Computational modeling and docking studies revealed a reduced interaction affinity between the LMBD1 protein and its partner protein ABCD4. These alterations contribute to a disrupted cascade mechanism in cobalamin (Cbl) metabolism resulting in development of variable clinical phenotypes. In our case, the proband was treated with intravenous hydroxocobalamin therapy and follow up showed a significant improvement in clinical symptoms of skin hyperpigmentation, angular cheilitis and aphthous ulcers. Hence the genomic analysis is essentially important for the appropriate genetic counseling and management of the disease.
- Open Access
- 12 January 2025
- Published by Springer Nature in Cureus
- Vol. 17 (1) , e77351
Variant Klinefelter Syndrome With Xq Trisomy (47,X,i(X)(q10),Y): A Case Report and Review of the Literature
Variant Klinefelter syndrome (VKS) presents with variable phenotypes, caused by the involvement of different genetic abnormalities leading to delays in confirming diagnosis and, therefore, delays in early management of this disorder. We describe a male with VKS and trisomy Xq resulting from an isochromosome X(i(Xq10)). He had characteristics of classical KS such as azoospermia, hypergonadotropic hypogonadism with elevated follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels, and bilateral atrophic testes. He achieved a normal intelligence level. However, we observed a normal stature appropriate for his height. There was no history of developmental delays or learning problems during childhood. His karyotype was found to be 47,X,i(X)(q10),Y, which indicates that extra copies of the long arm of Xq (trisomy Xq) have phenotypic expression. In conclusion, Trisomy Xq does not affect stature and neurological development and does not express classical phenotypes during early childhood. Hence, the cytogenetic screening of sex chromosomal abnormalities is important in cases of hypergonadotropic hypogonadism and testicle abnormality, which can help in appropriate genetic counseling.
- 12 January 2025
- Published by Springer Nature in Cureus
- Vol. 17 (1) , e77351
Open AccessVariant Klinefelter Syndrome With Xq Trisomy (47,X,i(X)(q10),Y): A Case Report and Review of the Literature
Variant Klinefelter syndrome (VKS) presents with variable phenotypes, caused by the involvement of different genetic abnormalities leading to delays in confirming diagnosis and, therefore, delays in early management of this disorder. We describe a male with VKS and trisomy Xq resulting from an isochromosome X(i(Xq10)). He had characteristics of classical KS such as azoospermia, hypergonadotropic hypogonadism with elevated follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels, and bilateral atrophic testes. He achieved a normal intelligence level. However, we observed a normal stature appropriate for his height. There was no history of developmental delays or learning problems during childhood. His karyotype was found to be 47,X,i(X)(q10),Y, which indicates that extra copies of the long arm of Xq (trisomy Xq) have phenotypic expression. In conclusion, Trisomy Xq does not affect stature and neurological development and does not express classical phenotypes during early childhood. Hence, the cytogenetic screening of sex chromosomal abnormalities is important in cases of hypergonadotropic hypogonadism and testicle abnormality, which can help in appropriate genetic counseling.
- 5 March 2024
- Published by S. Karger AG in Oncology
- Vol. 102 (10) , 897-906
Comprehensive Study of Chromosomal Copy Number Variations and Genomic Variations Predicting Overall Survival in Myelodysplastic Syndromes
Introduction: Myelodysplastic syndrome (MDS) is a heterogeneous disease characterized by cytopenia, marrow dysplasia and has a propensity to develop into acute myeloid leukemia. The disease progression is majorly affected by genetic defects. However, about 40–50% of patients with MDS present with a normal karyotype and develop different courses of disease. Hence, there remains a room to advance the biological understanding and find molecular prognostic markers for cytogenetically normal MDS. Methods: We performed a high-resolution CGH + SNP array along with next-generation sequencing (NGS) of 77 primary diagnosed MDS patients, and also they were clinically followed up. Results: Our study revealed 82 clinically significant genomic lesions (losses/gains) in 49% of MDS patients. CGH + SNP array reduced the proportion of normal karyotype by 30%. SNP array in combination with NGS confirmed the biallelic loss of function of the TP53 gene (2/6), which is a clinically relevant biomarker and new genetic-based MDS entity, i.e., MDS-biTP53, as per the new WHO classification 2022. Genomic region 2p22.3 presented with frequent lesions and also with a more hazard ratio (2.7, 95% CI: 0.37–21) when analyzed by Kaplan-Meier survival analysis. Conclusion: CGH + SNP array changed the cytogenetic and IPSS-R risk group in 18% and 13% of patients, respectively, with an improved prediction of prognosis. This study emphasizes the cytogenetic heterogeneity of MDS and highlights that abnormality with chromosome 2 may have a diagnostic and prognostic impact.
- 5 March 2024
- Published by S. Karger AG in Oncology
- Vol. 102 (10) , 897-906
Comprehensive Study of Chromosomal Copy Number Variations and Genomic Variations Predicting Overall Survival in Myelodysplastic Syndromes
Introduction: Myelodysplastic syndrome (MDS) is a heterogeneous disease characterized by cytopenia, marrow dysplasia and has a propensity to develop into acute myeloid leukemia. The disease progression is majorly affected by genetic defects. However, about 40–50% of patients with MDS present with a normal karyotype and develop different courses of disease. Hence, there remains a room to advance the biological understanding and find molecular prognostic markers for cytogenetically normal MDS. Methods: We performed a high-resolution CGH + SNP array along with next-generation sequencing (NGS) of 77 primary diagnosed MDS patients, and also they were clinically followed up. Results: Our study revealed 82 clinically significant genomic lesions (losses/gains) in 49% of MDS patients. CGH + SNP array reduced the proportion of normal karyotype by 30%. SNP array in combination with NGS confirmed the biallelic loss of function of the TP53 gene (2/6), which is a clinically relevant biomarker and new genetic-based MDS entity, i.e., MDS-biTP53, as per the new WHO classification 2022. Genomic region 2p22.3 presented with frequent lesions and also with a more hazard ratio (2.7, 95% CI: 0.37–21) when analyzed by Kaplan-Meier survival analysis. Conclusion: CGH + SNP array changed the cytogenetic and IPSS-R risk group in 18% and 13% of patients, respectively, with an improved prediction of prognosis. This study emphasizes the cytogenetic heterogeneity of MDS and highlights that abnormality with chromosome 2 may have a diagnostic and prognostic impact.
- 13 July 2023
- Published by Springer Nature in Annals of Hematology
- Vol. 102 (10) , 2683-2693
Genomic and computational analysis of four novel variants of MPL gene in Congenital Amegakaryocytic Thrombocytopenia
Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare, genetic, autosomal recessive disorder characterized by severe thrombocytopenia, due to inefficient bone marrow megakaryopoiesis eventually leading to aplasia. Majority of the cases are due to homozygous or compound heterozygous mutations in MPL gene encoding for thrombopoietin (THPO) receptor protein. CAMT can be diagnosed at early phase of life, with major complication of transfusion dependency and hematopoietic transplantation as only curative treatment. We have investigated the sequence variations in MPL gene of 7 bone marrow failure (BMF) subjects, who presented with clinically diverse phenotypes, through next generation sequencing (NGS). Plasma THPO levels were estimated using ELISA. Insilico sequence and structure-based analyses were performed to understand the structural and functional implications of mutations, identified through NGS. We studied 7 CAMT subjects suspected of BMF, who presented with severe thrombocytopenia followed by pancytopenia, bleeding manifestation and physical anomalies. The plasma THPO levels were significantly elevated (pMPL gene. These included 7 non-synonymous substitution, 1 nonsense substitution and 1 in-del mutations, of which 4 are novel mutations. Insilico analysis predicted damaging effects on THPO-R and its reduced affinity for THPO for all the identified mutations. CAMT is a rare disorder with diverse clinical phenotypes and diagnosis is challenging. The elevated plasma THPO levels should be considered for the primary diagnosis and prognosis of the disease. However, molecular analysis of MPL gene is important for the diagnosis and management of the disease through genetic counselling. Though the cytokines, THPO-R agonist are used for the treatment of CAMT, HSCT is the only curative therapy.
- 13 July 2023
- Published by Springer Nature in Annals of Hematology
- Vol. 102 (10) , 2683-2693
Genomic and computational analysis of four novel variants of MPL gene in Congenital Amegakaryocytic Thrombocytopenia
Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare, genetic, autosomal recessive disorder characterized by severe thrombocytopenia, due to inefficient bone marrow megakaryopoiesis eventually leading to aplasia. Majority of the cases are due to homozygous or compound heterozygous mutations in MPL gene encoding for thrombopoietin (THPO) receptor protein. CAMT can be diagnosed at early phase of life, with major complication of transfusion dependency and hematopoietic transplantation as only curative treatment. We have investigated the sequence variations in MPL gene of 7 bone marrow failure (BMF) subjects, who presented with clinically diverse phenotypes, through next generation sequencing (NGS). Plasma THPO levels were estimated using ELISA. Insilico sequence and structure-based analyses were performed to understand the structural and functional implications of mutations, identified through NGS. We studied 7 CAMT subjects suspected of BMF, who presented with severe thrombocytopenia followed by pancytopenia, bleeding manifestation and physical anomalies. The plasma THPO levels were significantly elevated (pMPL gene. These included 7 non-synonymous substitution, 1 nonsense substitution and 1 in-del mutations, of which 4 are novel mutations. Insilico analysis predicted damaging effects on THPO-R and its reduced affinity for THPO for all the identified mutations. CAMT is a rare disorder with diverse clinical phenotypes and diagnosis is challenging. The elevated plasma THPO levels should be considered for the primary diagnosis and prognosis of the disease. However, molecular analysis of MPL gene is important for the diagnosis and management of the disease through genetic counselling. Though the cytokines, THPO-R agonist are used for the treatment of CAMT, HSCT is the only curative therapy.
- 17 March 2023
- Published by Elsevier in Cancer Genetics
- Vol. 274-275, 26-29
Synergetic effect of Azacitidine and Sorafenib in treatment of a case of myeloid neoplasm with sole chromosomal abnormality t(8;22)(p11.2;q11.2)/BCR-FGFR1 rearrangement
- 17 March 2023
- Published by Elsevier in Cancer Genetics
- Vol. 274-275, 26-29
Synergetic effect of Azacitidine and Sorafenib in treatment of a case of myeloid neoplasm with sole chromosomal abnormality t(8;22)(p11.2;q11.2)/BCR-FGFR1 rearrangement